Weโre beyond proud and thankful to announce that Invitris has been selected for the ๐๐ฎ๐ซ๐จ๐ฉ๐๐๐ง ๐๐ง๐ง๐จ๐ฏ๐๐ญ๐ข๐จ๐ง ๐๐จ๐ฎ๐ง๐๐ข๐ฅ (๐๐๐) ๐๐๐๐๐ฅ๐๐ซ๐๐ญ๐จ๐ซ ๐ ๐ซ๐๐ง๐ญ! Out of ๐,๐๐๐ proposals, we are honored to be among the 71 chosen innovators.
The EIC Accelerator is the largest, most competitive European funding opportunity to startups. The goal of EIC Accelerator is to bring the most innovative companies to market faster, and to grow them to massive global players. For Invitris, this means multi-million โฌ funding through both a nondilutive grant and equity. “These funds will enable Invitris to scale our Phactory platform to develop personalized protein-based treatments and reach the next maturity stage of the company”, says Dr. Patrick Grossmann, CEO & co-founder of Invitris.
๐ This marks a significant step toward bringing personalized therapies closer to patients and advancing our mission to beat #AMR.
๐ A huge thank you to the EIC for this incredible opportunity, and congratulations to our fellow recipients!
Read more on: https://eic.ec.europa.eu/news/eic-accelerator-71-companies-selected-most-competitive-funding-round-so-far-2025-02-17_en
Press contact: https://invitris.com/contact/
